Evidence map›Paper›PMID 36017216›Full record

ReviewCardiovascular therapeutics2022

Obstructive Sleep Apnea and Cardiovascular Diseases: Sad Realities and Untold Truths regarding Care of Patients in 2022.

Satya Preetham Gunta, Roopesh Sai Jakulla, Aamer Ubaid, Kareem Mohamed, Abid Bhat, Angel López-Candales, Nicholas Norgard

Abstract readReview
In one paragraph

Review in Cardiovascular therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. The Global Burden of Obstructive Sleep Apnea.Diagnostics (Basel, Switzerland) · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Satya Preetham GuntaDepartment of Internal Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.ORCID https://orcid.org/0000-0003-2383-4342
Roopesh Sai JakullaDepartment of Internal Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Aamer UbaidDepartment of Internal Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.ORCID https://orcid.org/0000-0002-3096-2708
Kareem MohamedDepartment of Internal Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Abid BhatDepartment of Sleep Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Angel López-CandalesDepartment of Cardiovascular Diseases, University of Missouri-Kansas City, Kansas City, Missouri, USA.ORCID https://orcid.org/0000-0003-0019-651X
Nicholas NorgardDepartment of Internal Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.ORCID https://orcid.org/0000-0003-4612-0107

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obstructive sleep apnea (OSA) is one of the most common and serious sleep-related breathing disorders with a high prevalence among patients with cardiovascular (CV) diseases. Despite its widespread presence, OSA remains severely undiagnosed and untreated. CV mortality and morbidity are significantly increased in the presence of OSA as it is associated with an increased risk of resistant hypertension, heart failure, arrhythmias, and coronary artery disease. Evaluation and treatment of OSA should focus on recognizing patients at risk of developing OSA. The use of screening questionnaires should be routine, but a formal polysomnography sleep study is fundamental in establishing and classifying OSA. Recognition of OSA patients will allow for the institution of appropriate therapy that should alleviate OSA-related symptoms with the intent of decreasing adverse CV risk. In this review, we focus on the impact OSA has on CV disease and evaluate contemporary OSA treatments. Our goal is to heighten awareness among CV practitioners.

Indexed as

Cardiovascular DiseasesHeart FailureHypertensionSleep Apnea, ObstructiveHumansPolysomnographyRisk Factors

Identifiers

PMID36017216
PMCPMC9388301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.